JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S7

The Role of Nurses and Pharmacists in Identifying and Reporting Adverse Drug Reactions in Hospital Settings

Turki Abdullah Saeed Alghamdi[1], Abdulelah Mohammed Wajdi Halawani[2], Nader Abdullah Mohammedsaeed Alkhotani[3], Saleh Mohammed Saeed Alghamdi[4], Abed K Alkhairat[5], Ibrahim Ahmed Kharalla[6], Mai Ahmed Salem Hubaysh[7], Mohammed Hassan Abusharha[8], Abdullah Mohammed Amry[9], Mansour K Alkhairat[10], Hessah Abdurhman Alaobaidi[11], Nada Ali Asiri1[2], Fawaz Adel Khairullah[13], Nadia Ghanem Saeed Alrashedi[14], Asmaa Mohammed Fallatah[15]

1. Pharmacy Technicians, King Faisal Medical Complex - Taif
2. Pharmacist, KING ABDULAZIZ SPECIALIST HOSPITAL - TAIF.
3. Pharmacist, King Abdulaziz Specialist Hospital (KAASH) - Diabetic Center
4. Pharmacist , Children hospital in Taif
5. Prince Mohammed bin Nasser Hospital-Jazan, Cardiac Clinical Pharmacist
6. Al haramin train station center, Pharmacy technician
7. Ohud hospital, Pharmacist
8. osfan primary health care center, technician pharmacist.
9. Prince Mohammed Bin Nasser Hospital-Jazan, Pharmacist
10. Ministry of Health, Pharmacist
11. Nurse technician, Al Aziziyah Maternity And Children's Hospital
12. Nursing specialist, Mohayil dental center
13. King Abdulaziz Hospital, Nursing technician
14. King Salman bin Abdulaziz Medical City, Technician Nursing
15. Alazizia children Hospital, Nurse

ABSTRACT

This review was aimed to explore the roles of nurses and pharmacists in identifying and reporting adverse drug reactions (ADRs) in hospital settings, highlighting challenges and strategies for enhancing pharmacovigilance practices. Adverse drug reactions are a significant cause of morbidity and mortality in healthcare, necessitating robust systems for detection and reporting. Nurses and pharmacists play critical roles in ADR management, with nurses focusing on real-time patient monitoring, symptom identification, and patient education, while pharmacists contribute through medication reviews, risk assessments, and pharmacovigilance expertise. Despite their pivotal roles, barriers such as underreporting, knowledge gaps, and inadequate integration of reporting systems hinder effective ADR management. Strategies to address these challenges include ongoing education, streamlined reporting tools integrated into electronic health records, and fostering interdisciplinary collaboration. By empowering nurses and pharmacists with the necessary training, technology, and institutional support, healthcare systems can

improve ADR detection and reporting, enhancing patient safety and contributing to global pharmacovigilance efforts.

1. Introduction

Adverse drug reactions (ADRs) are unintended and harmful responses to medications that occur at normal therapeutic doses. They are a significant cause of morbidity and mortality in hospital settings, accounting for an estimated 5-10% of hospital admissions globally and leading to substantial healthcare costs and patient suffering. The early identification and reporting of ADRs are essential components of pharmacovigilance, which aims to improve drug safety, optimize patient outcomes, and inform regulatory actions. In hospital settings, nurses and pharmacists are uniquely positioned to play a pivotal role in these processes due to their close interactions with patients, expertise in drug therapy, and contributions to multidisciplinary care teams (1).

Nurses, as the primary caregivers at the bedside, are often the first to observe potential ADRs, given their continuous monitoring of patients' physical and emotional responses to medications. Their role extends beyond observation to include accurate documentation, communication with other healthcare providers, and educating patients about recognizing and reporting potential ADRs. Pharmacists, on the other hand, contribute to ADR management by applying their specialized knowledge of pharmacology, conducting medication reviews, and assessing the risk of ADRs through drug-drug interaction checks and laboratory data analysis. Together, these professionals form the backbone of hospital pharmacovigilance efforts, ensuring that ADRs are detected, managed, and reported efficiently. (2)

Despite their critical roles, ADR identification and reporting remain underutilized in many healthcare systems due to various barriers. Underreporting, which affects up to 90% of ADR cases worldwide, is driven by factors such as lack of time, inadequate training, fear of professional liability, and the absence of streamlined reporting systems. Moreover, the complexity of recognizing ADRs—particularly delayed or idiosyncratic reactions—adds to the challenge, necessitating a systematic and collaborative approach to pharmacovigilance (3).

This review explores the complementary roles of nurses and pharmacists in identifying and reporting ADRs in hospital settings. It emphasizes the processes involved in monitoring patients, assessing suspected ADRs, and utilizing structured reporting systems. The review also highlights challenges in ADR reporting and outlines strategies to enhance pharmacovigilance practices, including training, interdisciplinary collaboration, and the integration of technology. By addressing these aspects, this discussion underscores the importance of empowering nurses and pharmacists to lead pharmacovigilance initiatives, ultimately improving medication safety and patient care.

2. Review:

1. The Role of Nurses in Identifying and Reporting ADRs

1.1. Monitoring and Identifying ADRs

Nurses are uniquely positioned to detect adverse drug reactions (ADRs) due to their direct and continuous engagement with patients. Through routine assessments, they monitor vital signs, physical symptoms, and behavioral changes that may indicate an ADR. For example, a nurse caring for a patient receiving antibiotics might recognize signs of an allergic reaction, such as rash, pruritus, or dyspnea, which are common indicators of hypersensitivity (1). Their proximity to patients allows for early recognition of subtle symptoms that might be overlooked in intermittent physician evaluations. Nurses, as the primary caregivers, are often the first to identify potential ADRs. Their frequent interactions with patients allow them to monitor for subtle changes in physical, emotional, and behavioral states that may indicate a drug reaction. For instance:

Vital Sign Changes: Hypotension, tachycardia, or fever may signal an allergic or toxic response to a medication (1). Visible Reactions: Rashes, swelling, or hives can be early signs of hypersensitivity reactions. Behavioral Changes: Altered mental states, such as confusion or agitation, may be linked to CNS drug effects.

Nurses often employ standardized tools to assess the probability of a suspected ADR. For example:

The Naranjo Algorithm evaluates whether a symptom is drug-related by considering factors like the timing of drug administration, dose adjustment effects, and alternative explanations (2).

Nurses educate patients to recognize and report possible ADR symptoms, especially for high-risk drugs such as anticoagulants or chemotherapy agents. This empowerment improves early detection and facilitates timely intervention.

1.2. Documentation and Communication

Nurses document ADRs in patient records, including detailed descriptions of symptoms, suspected drugs, dosage, and timing. Accurate documentation serves multiple purposes:

- Ensures continuity of care by informing the healthcare team.
- Contributes data for pharmacovigilance databases, supporting broader drug safety initiatives.

Nurses play a crucial role in educating patients and caregivers about potential ADRs, particularly for high-risk medications like anticoagulants or chemotherapy agents. By explaining common symptoms and the importance of timely reporting, nurses empower patients to take an active role in their care. This collaborative approach improves the likelihood of early detection and intervention (3). Nurses collaborate with physicians and pharmacists to validate suspected ADRs and develop management plans. Effective communication ensures that the patient's care is adjusted appropriately to avoid further harm (3).

1.3. Participation in Reporting Systems

Within hospitals, nurses report ADRs to pharmacovigilance units or ADR committees, where reports are aggregated and analyzed for patterns. Nurses contribute to databases such as the FDA's MedWatch or the WHO's Individual Case Safety Report (ICSR) system, ensuring that ADRs are included in global pharmacovigilance efforts (4). Nurses are often limited by time constraints and unfamiliarity with reporting protocols. Training programs and simplified reporting tools can address these challenges, encouraging more frequent and accurate submissions.

---

2. The Role of Pharmacists in Identifying and Reporting ADRs

2.1. Expertise in Drug Use and Safety

1. Risk Identification During Medication Reconciliation

Pharmacists review patients' medication histories to identify potential risks, including:

Drug-drug interactions, such as combining anticoagulants with NSAIDs, which increases bleeding risk. Contraindications, particularly in patients with comorbidities or organ dysfunction (5).

2. Laboratory Data Monitoring

Pharmacists analyze laboratory results to detect signs of drug toxicity:

Elevated liver enzymes indicating hepatotoxicity from drugs like paracetamol. Renal function tests to identify nephrotoxicity from aminoglycosides or contrast agents (6).

3. Identification of High-Risk Medications

Certain drug classes are frequently associated with ADRs, and pharmacists focus on monitoring their use:

Anticoagulants: Risk of bleeding.

Antibiotics: Hypersensitivity reactions, including anaphylaxis.

Chemotherapeutic Agents: Cytotoxic effects on non-target tissues.

2.2. Reporting and Analysis

Pharmacists assess ADRs based on factors such as type (Type A predictable or Type B idiosyncratic), severity, and causality. For instance:

Type A reactions, like dose-dependent toxicity, are often preventable through dose adjustments.

Type B reactions, such as hypersensitivity, require immediate cessation of the drug

and appropriate treatment (7). Pharmacists and nurses work together to streamline ADR reporting processes. Their combined input ensures that reporting systems are user-friendly and align with clinical workflows, encouraging greater participation from healthcare staff.

Pharmacists submit ADR data to hospital committees and national regulatory agencies, such as:

The FDA's Adverse Event Reporting System (FAERS). The European Medicines Agency (EMA) EudraVigilance database.

Pharmacists train nurses, physicians, and other healthcare workers in recognizing and managing ADRs, fostering a culture of safety and awareness.

---

3. Collaborative Efforts Between Nurses and Pharmacists

Pharmacists rely on nurses for real-time observations of patient responses, while nurses depend on pharmacists for expertise in drug safety. Regular interdisciplinary meetings enhance collaboration and improve ADR detection and management. Pharmacists and nurses work together to establish standardized protocols for ADR reporting, ensuring clarity and consistency across teams. Collaborative efforts focus on adjusting treatment plans based on ADR reports, ensuring patient safety and therapeutic efficacy (8).

---

4. Challenges in ADR Reporting

Up to 90% of ADRs are underreported globally due to lack of awareness, fear of legal consequences, or time constraints (9). Many nurses and pharmacists lack formal training in pharmacovigilance, leading to missed opportunities for ADR detection (10). Complex reporting systems and insufficient integration with electronic health records (EHRs) hinder efficient ADR reporting (11). Pharmacists play a pivotal role in hospital pharmacovigilance committees, where they analyze ADR data to identify trends and propose system-level interventions. By submitting reports to external databases like FAERS or EudraVigilance, pharmacists contribute to the global understanding of drug safety profiles (12).

---

5. Strategies to Enhance ADR Identification and Reporting

1. Educational Programs

Regular workshops on ADR recognition and reporting for nurses and pharmacists. Incorporating pharmacovigilance into medical and pharmacy school curricula.

2. Simplified Reporting Systems

Integrating user-friendly ADR reporting tools into EHRs. Developing mobile apps for real-time ADR reporting at the point of care.

3. Feedback and Recognition

Providing feedback to healthcare professionals on reported ADRs to encourage continued participation. Recognizing contributions to ADR reporting as part of professional evaluations.

4. Strengthening Pharmacovigilance Infrastructure

Establishing dedicated pharmacovigilance teams in hospitals to coordinate reporting and analyze trends. Promoting interdisciplinary collaboration through regular meetings and case reviews.

3. Conclusion

The roles of nurses and pharmacists in identifying and reporting adverse drug reactions are complementary and critical for maintaining patient safety in hospital settings. Nurses' bedside observations and pharmacists' pharmacological expertise form the foundation of an effective pharmacovigilance system. Addressing barriers to ADR reporting, including underreporting and knowledge gaps, requires targeted education, simplified reporting tools, and interdisciplinary collaboration. By empowering nurses and pharmacists with the tools and training needed for effective ADR management, healthcare systems can improve medication safety, enhance therapeutic outcomes, and contribute to global pharmacovigilance efforts.

Despite their pivotal roles, challenges such as underreporting, inadequate training, and systemic barriers like complex reporting processes hinder effective ADR management. Addressing these challenges requires a multifaceted approach, including ongoing education for nurses and pharmacists, integration of user-friendly ADR reporting tools into electronic health records, and fostering a culture of safety through interdisciplinary collaboration and institutional support. Simplified reporting systems, coupled with feedback and recognition for healthcare professionals involved in ADR detection, can further enhance participation and accountability.

By empowering nurses and pharmacists with the resources, training, and technology needed to excel in their roles, healthcare systems can improve ADR detection, reporting accuracy, and overall medication safety. This collaborative approach not only reduces the burden of ADRs on patients and healthcare systems but also contributes to the global pharmacovigilance landscape, driving advancements in drug safety and the optimization of therapeutic outcomes. As pharmacovigilance evolves, the continued engagement of nurses and pharmacists will remain essential to achieving a safer and more effective healthcare system.

References

Lazarou J, Pomeranz BH, Corey PN. "Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective Studies." JAMA, 1998. DOI:10.1001/jama.1998.03440040057029.

Naranjo CA, et al. "A Method for Estimating the Probability of Adverse Drug Reactions." Clinical Pharmacology & Therapeutics, 1981. DOI:10.1038/clpt.1981.154.

Coleman JJ, Pontefract SK. "Adverse Drug Reactions." Clinical Medicine Journal, 2016. DOI:10.7861/clinmedicine.16-5-481.

World Health Organization (WHO). "Pharmacovigilance: Ensuring the Safe Use of Medicines." WHO

Report, 2004. Available at: https://www.who.int.

Kannan G, et al. "Medication Reconciliation in Hospitalized Patients: The Role of Pharmacists." Journal of Pharmacy Practice, 2017. DOI:10.1177/0897190016678477.

Barbarello-Andrews L. "Pharmacists' Role in Detecting and Preventing Adverse Drug Reactions." Pharmacy Times, 2018. Available at: https://www.pharmacytimes.com.

Edwards IR, Aronson JK. "Adverse Drug Reactions: Definitions, Diagnosis, and Management." The Lancet, 2000. DOI:10.1016/S0140-6736(00)02042-1.

Moore N. "Pharmacovigilance: The Role of Healthcare Professionals in ADR Reporting." Therapeutics and Clinical Risk Management, 2016. DOI:10.2147/TCRM.S99874.

Lopez-Gonzalez E, Herdeiro MT, Figueiras A. "Determinants of Under-Reporting of Adverse Drug Reactions: A Systematic Review." Drug Safety, 2009. DOI:10.2165/00002018-200932020-00004.

Al Dweik R, Stacey D, Kohen D, Yaya S. "Factors Affecting Patient Safety Competencies and Pharmacovigilance Training Among Healthcare Professionals." BMC Health Services Research, 2021. DOI:10.1186/s12913-021-06575-w.

Nebeker JR, Barach P, Samore MH. "Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting." Annals of Internal Medicine, 2004. DOI:10.7326/0003-4819-140-10-200405180-00008.

FDA MedWatch Program. "Safety Information and Adverse Event Reporting Program." FDA Resources, 2021. Available at: https://www.fda.gov/medwatch.